Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 46708-296

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 46708-296). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

10 mg 30's Bottle Pack (Donepezil 10mg)

10 mg 30's Bottle Pack (Donepezil 10mg)
This text is a label from a medication called Donepezil Hydrochloride USP. It provides information on the dosage and use of the medication, as well as storage instructions. It also includes the NDC code, information on the manufacturer and pharmacist's instructions on dispensing.*
FDA Label Image

5 mg 30's Bottle Pack (Donepezil 5mg)

5 mg 30's Bottle Pack (Donepezil 5mg)
This is a label of Donepezil Hydrochloride medication manufactured by Alembic Pharmaceuticals Limited in India. It comes in tablet form and is dispensed in tight containers. It is advised to store it at room temperature and the pharmacist should include a patient information sheet. The Lot and EXP numbers are not available.*
FDA Label Image

Figure 1 (Donepezil Figure1)

Figure 1 (Donepezil Figure1)
FDA Label Image

Figure 10 (Donepezil Figure10)

Figure 10 (Donepezil Figure10)
The text describes a graph showing the cumulative percentage of patients completing six months of a double-blind treatment, with particular changes from baseline in ADCS-ADL-Severe Scores. The graph is labeled as Figure 10 and displays the data in a line graph format.*
FDA Label Image

Figure 2 (Donepezil Figure2)

Figure 2 (Donepezil Figure2)
FDA Label Image

Figure 3 (Donepezil Figure3)

Figure 3 (Donepezil Figure3)
The text presents a figure (Figure 3) that shows the frequency distribution of CIBIC-plus Scores at Week 24. The figure includes a table with percentages of patients that experienced different levels of improvement in their condition (Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, Markedly Worse).*
FDA Label Image

Figure 4 (Donepezil Figure4)

Figure 4 (Donepezil Figure4)
The text describes a figure (Figure 4) showing the time-course of the change from baseline in ADAS-cog score for patients who completed a 15-week drug treatment study. The title of the figure suggests that it is related to drug treatment for some condition, but the specifics are not provided.*
FDA Label Image

Figure 5 (Donepezil Figure5)

Figure 5 (Donepezil Figure5)
FDA Label Image

Figure 6 (Donepezil Figure6)

Figure 6 (Donepezil Figure6)
FDA Label Image

Figure 7 (Donepezil Figure7)

Figure 7 (Donepezil Figure7)
FDA Label Image

Figure 8 (Donepezil Figure8)

Figure 8 (Donepezil Figure8)
This text appears to be a figure caption from a medical or scientific publication about a study on patients receiving double-blind treatment. The figure is likely a graph that shows the cumulative percentage of patients based on changes from baseline in SIB scores (which is not defined in the text). Therefore, the description is: "Figure caption displaying a graph of the cumulative percentage of patients completing 6 months of double-blind treatment, based on changes from baseline in SIB scores."*
FDA Label Image

Structure (Donepezil Structure)

Structure (Donepezil Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.